LEGN PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

LEGN ▲ +27.87% at T+5d

LONG call ✓ call won +27.87% · α vs SPY +30.62% · entry $25.51 → $32.62

Next anchor: T+20d in 15d

Last close $35.87 (close Jun 12) · +40.61% from $25.51 entry

Entry anchored
Jun 1, 09:59 AM ET
via Databento tick

T+1d

+42.22%

call +42.22% · α +42.07%

$36.28

settled 13d ago

T+5d

+27.87%

call +27.87% · α +30.62%

$32.62

settled 7d ago

T+20d

—

call — · α —

—

in 15d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Legend Biotech presented early clinical data for LB2102 (DLL3 CAR-T) in SCLC/LCNEC at ASCO, showing manageable safety and encouraging efficacy (28.6% ORR at higher doses), alongside updated CARVYKTI data reinforcing its durable efficacy in multiple myeloma. The data support pipeline progress but remain early-stage; no financial impact is reported.

Actionable Insight

Monitor for subsequent clinical readouts for LB2102 (dose escalation, expansion) and any regulatory updates for CARVYKTI label expansion; early data support pipeline value but not near-term revenue.

Key Facts

LB2102 Phase 1 data: ORR 20% overall, 28.6% at higher dose levels, DCR 78.6% at higher doses, median duration of response 6.5 months.
CARVYKTI data from CARTITUDE-4 show 30-month OS >85% in high-risk and standard-risk subgroups; no new safety signals.
LB2102 licensed to Novartis globally; Legend retains Phase 1 in US.
CARVYKTI approved in 18 countries, >10,000 patients treated.
No financial or guidance figures provided in the press release.

Financial Impact

No financial figures disclosed; stock impact likely from clinical sentiment rather than revenue.

Risk Factors

LB2102 is in early Phase 1; efficacy and safety remain unproven in larger trials.
Competition from other DLL3-targeted therapies (e.g., bispecifics, ADCs).
CARVYKTI faces potential competition from other BCMA CAR-T and bispecifics.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

87% bullish (23 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3304508

12 reports for LEGN

T+1T+5T+20T+60

75% Hit rate 6 of 8 directional calls best @ T+60▲ +83.95%Mar 10, 2026

Filters

Reports for LEGN — sortable, filterable
	Type				Now
Jun 14, 2026 1d ago	Press Release BULLISH ★ 7/10	—	awaiting T+1	—	—
Jun 2, 2026 12d ago	6-K BULLISH ★ 7/10	$36.28 $35.98	▼ −0.83%	▼ −0.13%	$35.87 (−1.13%)
Jun 2, 2026 12d ago	Press Release BULLISH ★ 7/10	$36.28 $35.98	▼ −0.83%	▼ −0.13%	$35.87 (−1.13%)
Jun 1, 2026 13d ago	6-K BULLISH ★ 6/10	$25.51 $36.28	▲ +42.22%	▲ +42.07%	$35.87 (+40.61%)
Jun 1, 2026 13d ago	Press Release BULLISH ★ 6/10	$25.51 $36.28	▲ +42.22%	▲ +42.07%	$35.87 (+40.61%)
May 21, 2026 24d ago	6-K NEUTRAL ★ 4/10	$29.37 $29.53	▲ +0.54%	▼ −0.04%	$35.87 (+22.13%)
May 21, 2026 24d ago	Press Release BULLISH ★ 7/10	$29.37 $29.53	▲ +0.54%	▼ −0.04%	$35.87 (+22.13%)
May 12, 2026 4w ago	6-K BULLISH ★ 7/10	$28.26 $28.67	▲ +1.45%	▲ +0.88%	$35.87 (+26.93%)
May 12, 2026 4w ago	Press Release BULLISH ★ 7/10	$28.26 $28.67	▲ +1.45%	▲ +0.88%	$35.87 (+26.93%)
Apr 28, 2026 6w ago	Press Release NEUTRAL ★ 2/10	$23.56 $22.77	▼ −3.35%	▼ −3.34%	$35.87 (+52.25%)

US Market Status

Market Closed — Opens in 4h 37m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access